MSD | Jotup

EQS-News: Caroline Jacquin appointed Managing Director of CHEPLAPHARM France SAS

Retrieved on:

星期三, 四月 10, 2024

MSD, Levallois-Perret, Marketing, Cheplapharm Arzneimittel, Hospital

Caroline Jacquin will take over the management of CHEPLAPHARM France, based in Levallois-Perret, a subsidiary of the CHEPLAPHARM Group from Greifswald/Germany, in April 2024.

Key Points:

Caroline Jacquin will take over the management of CHEPLAPHARM France, based in Levallois-Perret, a subsidiary of the CHEPLAPHARM Group from Greifswald/Germany, in April 2024.
The previous Managing Director of CHEPLAPHARM France, Isabelle Dalle, is retiring.
Caroline Jacquin, an experienced pharmaceutical manager, is taking over the position of Managing Director of the French subsidiary.
"I am delighted that we have been able to fill the position of the Managing Director of CHEPLAPHARM France with such a high-profile candidate as Caroline Jacquin.

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Retrieved on:

星期一, 四月 8, 2024

MSD, Employment, Fordham University, Biotechnology, CFO, Patient, Research, Merck, Gruntal & Co., Acquisition, IPO, MBA, Initial, Therapy, HSBC, Gene Mack, Pharmaceutical industry

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.

Key Points:

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
“We are thrilled to welcome Gene as our new CFO,” commented Gain CEO Matthias Alder.
Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023.
“I am excited to join Gain Therapeutics during this important stage of corporate growth and scientific progression.

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Retrieved on:

星期五, 三月 29, 2024

MSD, Biochemistry, Daiichi Sankyo, Patient, Knowledge, CMC, Cancer, University, Head, Spacecraft, Senior, Research and development, Drug development, Molecular biology, ANL, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.

Key Points:

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.
Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC at CStone Pharmaceuticals, at which he provided strategic leadership and oversight to the research, early clinical development, and CMC aspects of the entire CStone’s pipeline.
“We are very pleased to have Dr. Tse join our senior leadership team,” said Carsten Lu, CEO and Chairman of Adlai Nortye.
“I'm keen to leveraging my experiences with the outstanding team at Adlai Nortye and unlock the full potential of our pipeline.”

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on:

星期三, 三月 27, 2024

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points:

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
“During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.

Evaxion Announces Business Update and Full Year 2023 Financial Results

Retrieved on:

星期三, 三月 27, 2024

MSD, Conference, Innovation, Patient, Merck, Koala retrovirus, AI, Cancer, GHI, Merck & Co., Machine learning, European, Artificial intelligence

Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA.

Key Points:

Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA.
MSD GHI is now the single largest shareholder in Evaxion, with ownership of around 15%.
COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
Evaxion hosted an R&D Day on March 19, 2024, providing deeper insights into the validated and differentiated AI-Immunology™ platform.

Platform Science Raises $125 Million in Growth Capital

Retrieved on:

星期二, 四月 9, 2024

Platform Science , the leading edge application platform for transportation, announced today that it raised $125 million in growth capital to accelerate innovation in the commercial transportation sector.

Key Points:

Platform Science , the leading edge application platform for transportation, announced today that it raised $125 million in growth capital to accelerate innovation in the commercial transportation sector.
Platform Science also had strong participation from existing investors, including 8VC, NewRoad Capital Partners, and Prologis Ventures, underscoring their commitment to the company’s growth plans.
By doing so, we expect innovation to change transportation in the same way smartphones have changed our lives,” said Platform Science co-founder and CEO Jack Kennedy.
We look for opportunities that are driving impact at scale, and Platform Science is doing exactly this.

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Retrieved on:

星期二, 三月 19, 2024

MSD, EST, Koala retrovirus, Learning, AI, Neoplasm, Immune system, Machine learning, Vaccine, Collection, Medical device

The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here .

Key Points:

The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here .
The R&D Day features a series of talks providing in-depth insights into Evaxion's clinically validated AI-Immunology™ platform for vaccine target discovery, design and development.
Christian Kanstrup, CEO of Evaxion, expresses enthusiasm: “We have been looking forward to this exciting day and welcome everyone interested in learning more about our technology and its potential for saving and improving lives.
We believe that we hold a truly differentiated position driven by our validated AI-Immunology™ platform and the multi-disciplinary capability set we have built around it.

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

Retrieved on:

星期四, 四月 4, 2024

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.

Key Points:

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.
Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, including AstraZeneca, MSD, Novartis, Roche, and others.
With extended drug development experience, Zee helps to guide the statistical programming team at MMS to support some of the timely execution and evolving regulations for the development of NCEs.
Since 2020, the global biometrics CRO has experienced 133 percent growth in Europe.

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Retrieved on:

星期四, 四月 4, 2024

“KRAS is among the most prevalent mutations in cancer and KRAS G12C is the most common KRAS mutation in patients with non-small cell lung cancer,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.

Key Points:

“KRAS is among the most prevalent mutations in cancer and KRAS G12C is the most common KRAS mutation in patients with non-small cell lung cancer,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories.
The primary endpoints of the study are progression-free survival and overall survival, and key secondary endpoints include objective response rate and duration of response.
Preliminary safety and efficacy data from this trial were previously presented at the European Society for Medical Oncology (ESMO) Congress in 2023.
MK-1084 is being developed through a collaboration with Taiho Pharmaceutical Co. Ltd and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd.

Silver Lake to Take Endeavor Private

Retrieved on:

星期二, 四月 2, 2024

Silver Lake believes that when consolidating all of TKO’s value into Endeavor, the combined total enterprise value of $25 billion will make this the largest private equity sponsor public-to-private investment transaction in over a decade, and the largest ever in the media and entertainment sector.

Key Points:

Silver Lake believes that when consolidating all of TKO’s value into Endeavor, the combined total enterprise value of $25 billion will make this the largest private equity sponsor public-to-private investment transaction in over a decade, and the largest ever in the media and entertainment sector.
On the unaffected date, the equity value was $8.2 billion, and the premium to be paid by Silver Lake represents $4.6 billion more equity value to all Endeavor stockholders.
Ariel Emanuel, CEO of Endeavor, said: "Since 2012, Endeavor’s strategic partnership with Silver Lake and Egon Durban have been central to our evolution into the global sports and entertainment leader we are today.
Egon, Stephen, and the broader Silver Lake team have been and will continue to be phenomenal partners in Endeavor’s journey, and we look forward to the road ahead.”
Stephen Evans, Managing Director of Silver Lake and a Director of Endeavor, said: “The team at Silver Lake is proud of our longstanding partnership with Endeavor, marked by more than $3.5 billion of direct investment across six distinct transactions over 12 years.